Chao Huang

Dr. Chao Huang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
QXQipeng Xie
Qipeng Xie
Xiaohui HuaXiaohui Hua
Xiaohui Hua
CHChao Huang
Chao Huang
XLXin Liao
Xin Liao
ZTZhongxian Tian
Zhongxian Tian
CHChuanshu Huang
Chuanshu Huang
SOX2, a member of the SRY-related HMG-box (SOX) family, is abnormally expressed in many tumors and associated with cancer stem cell-like properties. Previous reports have shown that SOX2 is a biomarker for cancer stem cells in human bladder cancer (BC), and our most recent study has indicated that the inhibition of SOX2 by anticancer compound ChlA-F attenuates human BC cell invasion. We now investigated the mechanisms through which SOX2 promotes the invasive ability of BC cells. Our studies revealed that SOX2 promoted SKP2 transcription and increased SKP2-accelerated Sp1 protein degradation. As Sp1 is a transcriptionally regulated gene, HUR transcription was thereby attenuated, and, in the absence of HUR, FOXO1 mRNA was degraded fast, which promoted BC cell invasion. In addition, SOX2 promoted BC invasion through the upregulation of nucleolin transcription, which resulted in increased MMP2 mRNA stability and expression. Collectively, our findings show that SOX2 promotes BC invasion through both SKP2-Sp1-HUR-FOXO1 and nucleolin-MMP2 dual axes.

20 March 2025 in Advanced Science
Verified
Journal Article
Open access
HZHuayuan Zhao
Huayuan Zhao
XGXincheng Gao
Xincheng Gao
YJYangkai Jiang
Yangkai Jiang
YYYanchao Yu
Yanchao Yu
LWLiang Wang
Liang Wang
GJGuosong Jiang
Guosong Jiang
Fibroblast growth factor receptor (FGFR) family aberrations are common in urothelial cancer. The FGFR tyrosine kinase inhibitor erdafitinib has been approved for locally advanced or metastatic urothelial cancer with FGFR2/3 alterations. Despite the initial efficacy of erdafitinib, resistance cannot be avoided. The molecular mechanisms underlying erdafitinib resistance have not been well investigated. Here, genome‐wide CRISPR screen is performed and coatomer protein complex subunit α (COPA) is identified as a key target to enhance erdafitinib sensitivity. Functionally, the deficiency of COPA reduces the proliferation of FGFR‐altered bladder cancer cells upon erdafitinib treatment. Mechanistically, COPA knockout increases the degradation of leucine‐rich pentatricopeptide repeat containing (LRPPRC) protein, leading to reduced inhibitor of DNA binding 3 (ID3) mRNA stability in an m6A‐dependent manner. Collectively, these findings reveal a novel mechanism of erdafitinib resistance, providing a potential therapeutic target for FGFR‐altered bladder cancer.

Verified
Journal Article
Open access
PDF file
HZHe Zhong
He Zhong
NWNing Wang
Ning Wang
HZHui Zhang
Hui Zhang
MCMin Chen
Min Chen
XLXin Liao
Xin Liao
CHChao Huang
Chao Huang
Circular RNAs (circRNAs) have been reported to be closely associated with tumor progression in multiple malignancies. However, the specific mechanism by which circPRKCA influences tumor progression has not been fully elucidated. CircPRKCA is highly expressed in non-small cell lung cancer (NSCLC) tissues and cells. Knockdown of circPRKCA inhibits the malignant behaviors of NSCLC cells. RNA sequencing results revealed that FRMD6 and SNAI2 mRNAs are positively correlated with circPRKCA. Subsequently, we proved that circPRKCA acts as a molecular sponge for miR-200b-3p. Additionally, miR-200b-3p binds to the 3′ untranslated regions (3′UTRs) of FRMD6 and SNAI2 mRNAs to promote their degradation. Overexpression of circPRKCA thereby suppresses this degradation process and coun-teracts the tumor-suppressive effects induced by miR-200b-3p. CircPRKCA functions as the sponge of miR-200b-3p, suppressing the SNAI2/FRMD6 mRNA degradation driven by miR-200b-3p and accelerating NSCLC progression.

7 July 2026 in BMC Medical Imaging
Verified
Journal Article
Open access
WLWeiwei Liu
Weiwei Liu
BGBingxin Gong
Bingxin Gong
GZGuilin Zhang
Guilin Zhang
YGYusheng Guo
Yusheng Guo
XFXiaona Fu
Xiaona Fu
LYLian Yang
Lian Yang
Background: This study aimed to develop a CT-based delta-radiomics model for personalized prediction of postoperative prognosis in bladder cancer patients and identification of differentially expressed genes associated with tumour recurrence. Materials and methods: This retrospective study included 316 patients with bladder cancer from Wuhan Union Hospital who underwent preoperative unenhanced and arterial-phase CT before surgical resection. Patients were randomly divided into training and internal validation cohorts at an 8:2 ratio. Radiomic features were extracted from tumor volumes of interest on both CT phases, and delta-radiomic features were calculated as arterial-phase features minus unenhanced-phase features. Feature selection was performed within the training cohort using statistical filtering, correlation analysis, and LASSO regression. Multiple machine-learning classifiers were evaluated, and a combined clinico-radiomic model was constructed by integrating the delta-radiomics score with selected clinical predictors. Model performance was assessed using ROC analysis, calibration, decision curve analysis, DeLong testing, and repeated stratified random splitting. An additional TCIA cohort of 33 patients was used for exploratory transcriptomic analysis. Results: After feature selection, nine delta-radiomic features derived from paired unenhanced and arterial-phase CT images were retained for model construction. The LightGBM-based delta-radiomics model achieved AUCs of 0.837 and 0.822 in the training and validation cohorts, respectively. The combined clinical-radiomics model, constructed by integrating the delta-radiomics Rad-score with muscle invasion as a clinical predictor, achieved the best discrimination, with AUCs of 0.860 and 0.861 in the training and validation cohorts, respectively, and showed stable validation performance in 100 repeated splits. High radiomics scores were associated with significantly shorter recurrence-free survival. Exploratory transcriptomic analysis showed enrichment of immune-related pathways in the low-risk radiomic subgroup. Conclusions: Multiphasic CT-based delta-radiomics provides a non-invasive approach for predicting postoperative recurrence and stratifying prognosis in bladder cancer. A combined clinico-radiomic model incorporating delta-radiomics and muscle invasion achieved superior predictive performance and may support individualized postoperative risk assessment.